For Swiss drug and diagnostics giant Roche (Nasdaq:RHHBY), the hits just keep on coming. Already bruised by setbacks in the Avastin franchise, Roche announced Friday morning that the FDA rejected an accelerated approval application for T-DM1, a potentially major drug for metastatic breast cancer. As the originator of the technology behind the drug and Roche's partner, ImmunoGen (Nasdaq:IMGN) will also suffer for this surprising FDA decision.

IN PICTURES: 9 Simple Investing Ratios You Need To Know

Precision Munition for Resistant Patients
In very simplified terms, T-DM1 is a derivative of Roche's successful Herceptin drug. ImmunoGen found a way to add a cell-killing compound (DM1) to the HER2 binding antibody trastuzumab that is the active component of Herceptin. What this means in practice is that T-DM1 hones in on the HER2+ cancer cells and delivers a lethal dose, while sparing the sort of system-wide toxicity that so often limits powerful drugs. In early stage studies this drug has shown progression-free survival of five to seven months and Roche had been talking about this drug as a $2-$5 billion/year opportunity.

The Timeline Slides Back
Roche had hoped to achieve an accelerated approval from the FDA that would have likely meant approval in early 2011. The FDA allows these approvals in circumstances where there are serious diseases with minimal options. Although that would certainly seem to apply to third-line metastatic breast cancer (that is, breast cancer that has spread beyond the breast and showed resistance to two prior drugs), the FDA ruled in this case that the patients in Roche's study groups had not exhausted all available options.

Regardless of whether the FDA is being overly literal or not, there is little than Roche can do about it. Now, instead of an early 2011 approval, Roche is looking at a filing in mid-2012, and a possible follow-on filing for T-DM1 as a front-line therapy in 2014. Given the normal FDA review timeline, that means a likely delay of two and a half years. (For related reading, see Measuring The Medicine Makers.)

Where Do They Go Now?
This is clearly a significant setback for ImmunoGen. T-DM1 is the company's only late-stage candidate, and it will be years before the company's other pipeline candidates, IMGN901 and earlier candidates partnered with Sanofi-Aventis (NYSE:SNY) and Biogen Idec (Nasdaq:BIIB), get close to the market.

Moreover, ImmunoGen could certainly have used the milestone payment from Roche that is tied to approval, as well as the royalties from actual sales. With about $110 million in cash and a $10 million quarterly burn rate, ImmunoGen could find itself cash-constrained without additional milestones or financing.

For Roche too, this is a major setback. Roche has been struggling to generate enthusiasm lately, as investors increasingly seem to perceive it as a company with low earnings growth potential and relatively near-term risk of biologics competition from Teva (Nasdaq:TEVA) and Mylan (NYSE:MYL). As a valuable line extension of the Herceptin franchise, this delay on T-DM1 does the company no favors in terms of trying to get investors on board with better near-term expectations.

The Bottom Line
Figuring on a two-and-a-half year delay in T-DM1 (but eventual approval all the same), this news would seem to reduce the fair value of ImmunoGen by about $2 per share. Since the market has driven the stock down by $3, patient risk-tolerant investors may want to take a look - the data on this drug still looks good, and the real damage from this announcement is a time value of money question.

For Roche, the impact is likely to be more severe on perception than financials. T-DM1 should be a lucrative product for the company, but Roche is large enough that this delay is not a serious wound. Still, the seemingly constant stream of bad news is taking a toll on perception and weighing heavily on the stock. Roche shares look quite cheap for the long haul, but will likely be frustrating to investors who are not patient long-term value mavens. (For more, see Big Pharma's Big Problem.)

Use the Investopedia Stock Simulator to trade the stocks mentioned in this stock analysis, risk free!

Related Articles
  1. Mutual Funds & ETFs

    The 4 Best Buy-and-Hold ETFs

    Explore detailed analyses of the top buy-and-hold exchange traded funds, and learn about their characteristics, statistics and suitability.
  2. Stock Analysis

    The Biggest Risks of Investing in Netflix Stock

    Examine the current state of Netflix Inc., and learn about three of the major fundamental risks that the company is currently facing.
  3. Stock Analysis

    What Seagate Gains by Acquiring Dot Hill Systems

    Examine the Seagate acquisition of Dot Hill Systems, and learn what Seagate is looking to gain by acquiring Dot Hill's software technology.
  4. Mutual Funds & ETFs

    What Exactly Are Arbitrage Mutual Funds?

    Learn about arbitrage funds and how this type of investment generates profits by taking advantage of price differentials between the cash and futures markets.
  5. Investing News

    Ferrari’s IPO: Ready to Roll or Poor Timing?

    Will Ferrari's shares move fast off the line only to sputter later?
  6. Stock Analysis

    5 Cheap Dividend Stocks for a Bear Market

    Here are five stocks that pay safe dividends and should be at least somewhat resilient to a bear market.
  7. Investing

    How to Win More by Losing Less in Today’s Markets

    The further you fall, the harder it is to climb back up. It’s a universal truth that is painfully apparent in the investing world.
  8. Fundamental Analysis

    Use Options Data To Predict Stock Market Direction

    Options market trading data can provide important insights about the direction of stocks and the overall market. Here’s how to track it.
  9. Stock Analysis

    2 Oil Stocks to Buy Right Now (PSX,TSO)

    Can these two oil stocks buck the trend?
  10. Investing News

    What Alcoa’s (AA) Breakup Means for Investors

    Alcoa plans to split into two companies. Is this a bullish catalyst for investors?
  1. Can working capital be too high?

    A company's working capital ratio can be too high in the sense that an excessively high ratio is generally considered an ... Read Full Answer >>
  2. How do I use discounted cash flow (DCF) to value stock?

    Discounted cash flow (DCF) analysis can be a very helpful tool for analysts and investors in equity valuation. It provides ... Read Full Answer >>
  3. How do dividends affect retained earnings?

    When a company issues a cash dividend to its shareholders, the retained earnings listed on the balance sheet are reduced ... Read Full Answer >>
  4. What is the formula for calculating compound annual growth rate (CAGR) in Excel?

    The compound annual growth rate, or CAGR for short, measures the return on an investment over a certain period of time. Below ... Read Full Answer >>
  5. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  6. When does the fixed charge coverage ratio suggest that a company should stop borrowing ...

    Since the fixed charge coverage ratio indicates the number of times a company is capable of making its fixed charge payments ... Read Full Answer >>

You May Also Like

Trading Center
You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!